PT3061821T - Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos - Google Patents
Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicosInfo
- Publication number
- PT3061821T PT3061821T PT16151747T PT16151747T PT3061821T PT 3061821 T PT3061821 T PT 3061821T PT 16151747 T PT16151747 T PT 16151747T PT 16151747 T PT16151747 T PT 16151747T PT 3061821 T PT3061821 T PT 3061821T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- treatment
- receptor activation
- muscarinic receptor
- disorders ameliorated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21385309P | 2009-07-22 | 2009-07-22 | |
US28265810P | 2010-03-15 | 2010-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3061821T true PT3061821T (pt) | 2019-09-05 |
Family
ID=43497520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT16151747T PT3061821T (pt) | 2009-07-22 | 2010-07-21 | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
Country Status (10)
Country | Link |
---|---|
US (9) | US20110020423A1 (pt) |
EP (3) | EP3646870A1 (pt) |
JP (6) | JP2012533621A (pt) |
CA (1) | CA2804215C (pt) |
DK (1) | DK3061821T3 (pt) |
ES (1) | ES2742728T3 (pt) |
HU (1) | HUE044653T2 (pt) |
PL (1) | PL3061821T3 (pt) |
PT (1) | PT3061821T (pt) |
WO (1) | WO2011011060A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
EP3646870A1 (en) * | 2009-07-22 | 2020-05-06 | Puretech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
EP2804842B1 (en) | 2012-01-20 | 2020-12-02 | Straumann Holding AG | Prosthetic element |
US20130289019A1 (en) * | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
LT3134386T (lt) | 2014-04-23 | 2020-08-10 | Takeda Pharmaceutical Company Limited | Izoindolin-1-ono dariniai kaip cholinerginio muskarininio m1 receptoriaus teigiamo aloesterinio moduliatoriaus aktyvumas, skirtas alzheimerio ligos gydymui |
CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
JP2017533227A (ja) * | 2014-11-03 | 2017-11-09 | ウィリアム・ボーモント・ホスピタルWilliam Beaumont Hospital | 低活動膀胱症候群を治療するための方法 |
US20180015270A1 (en) * | 2015-01-30 | 2018-01-18 | Ligalli B.V. | Vaginal Drug Delivery Device |
WO2016144749A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Thomas N | Oxybutynin-xanomeline transdermal therapeutic system combinations |
CA2978214A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
CA2978201A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
UA121503C2 (uk) | 2015-06-26 | 2020-06-10 | Такеда Фармасьютікал Компані Лімітед | 2,3-дигідро-4h-1,3-бензоксазин-4-онові похідні як модулятори холінергічного мускаринового рецептора m1 |
WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
US10548899B2 (en) | 2015-10-20 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity |
US11801241B2 (en) * | 2017-03-03 | 2023-10-31 | The United States Government As Represented By The Department Of Veterans Affairs | Muscarinic M2 receptor blockade to delay or prevent onset of progressive memory decline |
MX2021003621A (es) | 2018-09-28 | 2022-04-13 | Karuna Therapeutics Inc | Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico. |
CA3131128A1 (en) * | 2019-02-22 | 2020-08-27 | Karuna Therapeutics, Inc. | Compounds and methods of deuterated xanomeline for treating neurological disorders |
WO2021097427A1 (en) * | 2019-11-15 | 2021-05-20 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
EP4061808A4 (en) * | 2019-11-18 | 2023-12-20 | Karuna Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELIEVED BY ACTIVATION OF THE MUSCARINE RECEPTOR |
WO2022072738A1 (en) * | 2020-09-30 | 2022-04-07 | The Regents Of The University Of California | System, software and methods of using software for predicting efficacy of alzheimer's disease treatments |
EP4091607A1 (en) * | 2021-05-18 | 2022-11-23 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics |
WO2023196952A2 (en) * | 2022-04-07 | 2023-10-12 | Karuna Therapeutics, Inc. | Methods for treating disorders ameliorated by muscarinic receptor activation |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647580A (en) | 1985-07-18 | 1987-03-03 | Syntex (U.S.A.) Inc. | Treatment of Alzheimer's disease |
US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
US5480651A (en) | 1992-03-16 | 1996-01-02 | Regents Of The University Of California | Composition and method for treating nicotine craving in smoking cessation |
HU221729B1 (hu) | 1993-08-19 | 2002-12-28 | Novo Nordisk A/S | Tiadiazolil-piridin-származékok alkalmazása antipszichotikus gyógyszerek előállítására |
US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
DE19612504C2 (de) * | 1996-03-29 | 2003-10-23 | Boehringer Ingelheim Kg | Neue Wirkstoffkompositionen |
GB9612710D0 (en) * | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
DK0821955T3 (da) * | 1996-08-01 | 2002-03-18 | Lilly Co Eli | Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse |
EP0821954A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
EP0821959A3 (en) | 1996-08-01 | 1998-09-16 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal |
EP0821956A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating disruptive behavior disorders |
EP0821958A3 (en) | 1996-08-01 | 1998-07-08 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression |
WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
RU2219179C2 (ru) | 1998-08-18 | 2003-12-20 | ЮСиБи С.А. | Азациклические соединения, фармацевтические композиции |
CN1660435A (zh) * | 2000-02-24 | 2005-08-31 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
JP2004502655A (ja) | 2000-06-30 | 2004-01-29 | イーライ・リリー・アンド・カンパニー | 精神病の処置のための組み合わせ療法 |
WO2002051440A1 (fr) * | 2000-12-22 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Medicaments de combinaison |
US6862890B2 (en) | 2001-01-30 | 2005-03-08 | Board Of Regents, University Of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
US20040224012A1 (en) | 2001-10-05 | 2004-11-11 | Pichit Suvanprakorn | Topical application and methods for administration of active agents using liposome macro-beads |
US20030068365A1 (en) | 2001-10-05 | 2003-04-10 | Pichit Suvanprakorn | Compositions and methods for administration of active agents using liposome beads |
DK1509492T3 (da) | 2002-01-25 | 2011-11-28 | Theravance Inc | Sedative hypnotiske midler med kort virkningsvarighed til anæstesi og sedation |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7439251B2 (en) * | 2002-05-03 | 2008-10-21 | Israel Institute For Biological Research | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
US20050085463A1 (en) | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
US20050250767A1 (en) | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
GB0307860D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
AU2004286855B2 (en) | 2003-10-29 | 2011-04-21 | Wyeth | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
ES2359375T3 (es) | 2003-11-04 | 2011-05-20 | Supernus Pharmaceuticals, Inc. | Formas de dosificación de dosis única diaria de trospio. |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP2088147A1 (en) | 2003-12-22 | 2009-08-12 | Arcadia Pharmaceuticals Inc. | Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
CA2582385A1 (en) | 2004-06-18 | 2005-12-18 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
GB0428170D0 (en) | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
GB0428180D0 (en) | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
US20060183733A1 (en) | 2005-02-11 | 2006-08-17 | Stephen Wills | Treating microvasculature diseases with acetyl cholinesterase inhibitors |
JP4732769B2 (ja) | 2005-03-04 | 2011-07-27 | 富士フイルム株式会社 | 内視鏡装置 |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
KR20080025079A (ko) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
EP2275095A3 (en) * | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
ES2365161T3 (es) | 2005-09-02 | 2011-09-23 | Theravida, Inc. | Terapia para el tratamiento de la vejiga hiperactiva. |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
TW200811105A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
WO2007128674A2 (en) * | 2006-05-04 | 2007-11-15 | Solvay Pharmaceuticals B.V. | Muscarinic agonists to treat impulse control disorders |
US7905852B2 (en) | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
US8097633B2 (en) * | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
WO2008076287A2 (en) | 2006-12-13 | 2008-06-26 | Tuel Stephen M | Methods of making pharmaceutical components for customized drug products |
GB0702416D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
GB0702385D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
EP2141992A1 (en) | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
JP2010539182A (ja) | 2007-09-12 | 2010-12-16 | グラクソ グループ リミテッド | 治療剤の新規組み合わせ |
WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
EP2200610B1 (en) | 2007-09-21 | 2018-01-10 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
TWI454288B (zh) | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | 藥物劑型 |
EP3178477A1 (en) | 2008-03-27 | 2017-06-14 | Chase Pharmaceuticals Corporation | Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia |
US20110119259A1 (en) | 2008-04-24 | 2011-05-19 | Trustees Of Boston University | Network biology approach for identifying targets for combination therapies |
GB0822077D0 (en) | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
AU2010221133A1 (en) * | 2009-03-05 | 2011-09-22 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
EP3646870A1 (en) | 2009-07-22 | 2020-05-06 | Puretech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
US8853219B2 (en) | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
GB2479213B (en) | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
JP2014516080A (ja) | 2011-06-08 | 2014-07-07 | エスティーアイ ファーマ, エルエルシー | 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 |
KR20200065113A (ko) | 2012-09-05 | 2020-06-08 | 체이스 파마슈티칼스 코포레이션 | 항콜린 신경보호 조성물 및 그 방법 |
CA2978214A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
WO2016144749A1 (en) | 2015-03-06 | 2016-09-15 | Chase Thomas N | Oxybutynin-xanomeline transdermal therapeutic system combinations |
CN109562137A (zh) | 2015-09-01 | 2019-04-02 | 第波生物公司 | 用于治疗与异常炎性反应有关的病况的方法和组合物 |
CA2996719A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
EP3405191A4 (en) | 2016-01-20 | 2019-09-04 | TheraVida, Inc. | METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS |
WO2017147104A1 (en) | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
MX2021003621A (es) | 2018-09-28 | 2022-04-13 | Karuna Therapeutics Inc | Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico. |
-
2010
- 2010-07-21 EP EP19180984.7A patent/EP3646870A1/en active Pending
- 2010-07-21 US US12/840,980 patent/US20110020423A1/en not_active Abandoned
- 2010-07-21 JP JP2012521617A patent/JP2012533621A/ja active Pending
- 2010-07-21 CA CA2804215A patent/CA2804215C/en active Active
- 2010-07-21 EP EP16151747.9A patent/EP3061821B1/en active Active
- 2010-07-21 DK DK16151747.9T patent/DK3061821T3/da active
- 2010-07-21 PT PT16151747T patent/PT3061821T/pt unknown
- 2010-07-21 WO PCT/US2010/002044 patent/WO2011011060A1/en active Application Filing
- 2010-07-21 EP EP10802549.5A patent/EP2456868A4/en not_active Withdrawn
- 2010-07-21 ES ES16151747T patent/ES2742728T3/es active Active
- 2010-07-21 PL PL16151747T patent/PL3061821T3/pl unknown
- 2010-07-21 HU HUE16151747 patent/HUE044653T2/hu unknown
-
2013
- 2013-04-09 US US13/858,985 patent/US20140099356A1/en not_active Abandoned
-
2014
- 2014-11-06 US US14/534,698 patent/US20150265593A1/en not_active Abandoned
-
2015
- 2015-01-30 JP JP2015016246A patent/JP2015083612A/ja active Pending
-
2016
- 2016-06-10 JP JP2016115901A patent/JP2016164201A/ja active Pending
-
2017
- 2017-01-06 US US15/400,108 patent/US10238643B2/en active Active
- 2017-10-11 JP JP2017197340A patent/JP7136545B2/ja active Active
-
2019
- 2019-02-07 US US16/270,206 patent/US10369143B2/en active Active
- 2019-02-28 US US16/289,165 patent/US10369144B2/en active Active
- 2019-06-18 US US16/444,206 patent/US10695339B2/en active Active
- 2019-09-13 JP JP2019166743A patent/JP2020023494A/ja active Pending
-
2020
- 2020-05-21 US US16/880,634 patent/US20200323839A1/en not_active Abandoned
-
2022
- 2022-09-08 JP JP2022143313A patent/JP2022168136A/ja active Pending
-
2023
- 2023-09-06 US US18/461,741 patent/US20240100039A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE044653T2 (hu) | 2019-11-28 |
EP2456868A1 (en) | 2012-05-30 |
US20200323839A1 (en) | 2020-10-15 |
CA2804215A1 (en) | 2011-01-27 |
EP3061821A1 (en) | 2016-08-31 |
US20190307739A1 (en) | 2019-10-10 |
JP2015083612A (ja) | 2015-04-30 |
ES2742728T3 (es) | 2020-02-17 |
JP2020023494A (ja) | 2020-02-13 |
EP3061821B1 (en) | 2019-07-10 |
CA2804215C (en) | 2019-10-01 |
US20140099356A1 (en) | 2014-04-10 |
PL3061821T3 (pl) | 2020-01-31 |
EP2456868A4 (en) | 2013-11-06 |
US20170112820A1 (en) | 2017-04-27 |
JP2018002738A (ja) | 2018-01-11 |
JP7136545B2 (ja) | 2022-09-13 |
JP2022168136A (ja) | 2022-11-04 |
US20110020423A1 (en) | 2011-01-27 |
US10238643B2 (en) | 2019-03-26 |
US20190192500A1 (en) | 2019-06-27 |
US10369143B2 (en) | 2019-08-06 |
DK3061821T3 (da) | 2019-08-26 |
US20190167658A1 (en) | 2019-06-06 |
JP2012533621A (ja) | 2012-12-27 |
WO2011011060A1 (en) | 2011-01-27 |
US10695339B2 (en) | 2020-06-30 |
JP2016164201A (ja) | 2016-09-08 |
EP3646870A1 (en) | 2020-05-06 |
US10369144B2 (en) | 2019-08-06 |
US20150265593A1 (en) | 2015-09-24 |
US20240100039A1 (en) | 2024-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3061821T (pt) | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos | |
IL217901A0 (en) | Treatment of bdnf-related disorders using laquninimod | |
RS57110B1 (sr) | Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim | |
GB0904285D0 (en) | Compounds for the treatment of metabolic disorders | |
PL2429507T3 (pl) | Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry | |
GB0904287D0 (en) | Compounds for the treatment of metabolic disorders | |
ZA201107490B (en) | 5-ht4 receptor agonist compounds for treatment of cognitive disorders | |
ZA201202346B (en) | Therapeutic agent for mood disorders | |
GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
IL214745A0 (en) | Treatment of insulin-resistant disorders | |
HRP20171418T1 (hr) | Terapeutsko sredstvo za poremećaje anksioznosti | |
HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
HU0900364D0 (en) | Preventive composition for treatment of disease of honey-bees caused by cck | |
IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
IL199979A0 (en) | Pharmaceutical compositions for treatments of neurological disorders | |
GB0904289D0 (en) | Compounds for the treatment of metabolic disorders | |
GB0904286D0 (en) | Compounds for the treatment of metabolic disorders | |
GB0904288D0 (en) | Compounds for the treatment of metabolic disorders | |
GB0904290D0 (en) | Compounds for the treatment of metabolic disorders |